FDA Panel Recommends Easing Peptide Regulations

An advisory panel to the U.S. Food and Drug Administration (FDA) has voted 8-6 to recommend that restrictions be eased on peptides such as BPC-157 and TB-500. These compounds, popular among wellness influencers and telehealth clinics, are not FDA-approved medications unlike GLP-1 drugs like Ozempic.

The panel's recommendation does not immediately legalize these peptides but signals a potential shift in their regulatory status. Some panel members with ties to the peptide industry supported the move, suggesting it could foster development. Health Secretary Robert F. Kennedy Jr., who led the panel, has previously expressed support for peptides and removed some from the FDA's high-risk list.

However, the decision has drawn criticism from some scientists and health professionals. Rita Jew, a pharmacist and president of the Institute for Safe Medication Practices, called the situation an "alarming" "Wild West" of unproven and unregulated drugs, raising concerns about safety and efficacy.

The FDA is expected to make a final decision after reviewing the panel's vote and public comments. This outcome could significantly influence the market and future use of peptides in the wellness sector.